Salim Syed

Stock Analyst at Mizuho

(1.94)
# 3,057
Out of 4,902 analysts
81
Total ratings
36.92%
Success rate
-7.32%
Average return

Stocks Rated by Salim Syed

Nkarta
Jun 10, 2025
Maintains: Outperform
Price Target: $16$14
Current: $2.05
Upside: +582.93%
Cytokinetics
May 29, 2025
Maintains: Outperform
Price Target: $103$84
Current: $39.21
Upside: +114.23%
Biogen
May 7, 2025
Maintains: Outperform
Price Target: $207$169
Current: $128.07
Upside: +31.96%
Amgen
May 7, 2025
Maintains: Neutral
Price Target: $235$280
Current: $297.87
Upside: -6.00%
Gilead Sciences
May 5, 2025
Maintains: Outperform
Price Target: $100$117
Current: $108.77
Upside: +7.57%
Wave Life Sciences
Nov 21, 2024
Maintains: Outperform
Price Target: $19$22
Current: $7.97
Upside: +176.04%
Vaxcyte
Sep 10, 2024
Maintains: Outperform
Price Target: $113$163
Current: $37.45
Upside: +335.25%
Atara Biotherapeutics
Aug 16, 2024
Upgrades: Outperform
Price Target: $25$18
Current: $9.45
Upside: +90.48%
Enliven Therapeutics
Apr 9, 2024
Initiates: Buy
Price Target: $34
Current: $22.49
Upside: +51.18%
CRISPR Therapeutics AG
Mar 6, 2024
Maintains: Buy
Price Target: $82$99
Current: $55.12
Upside: +79.61%
Maintains: Buy
Price Target: $60$53
Current: $46.75
Upside: +13.37%
Maintains: Buy
Price Target: $12$6
Current: $0.11
Upside: +5,135.60%
Maintains: Buy
Price Target: $28$21
Current: $0.91
Upside: +2,201.62%
Maintains: Buy
Price Target: $168$36
Current: $19.12
Upside: +88.33%